CD11b deficiency attenuates the ischemia/reperfusion‐induced AKI‐to‐CKD process by regulating macrophage polarization
The FASEB Journal · 2024
DOI: 10.1096/fj.202402318r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Huili Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Acute Kidney Injury, CD11b Antigen, Reperfusion Injury, Macrophages. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Clinical Research Center for Kidney Disease, Shanghai Key Laboratory of Kidney and Blood Purification.
Abstract (Originalsprache)
Severe acute kidney injury (AKI) is a risk factor for the future development of chronic kidney disease (CKD), and macrophages are an essential cell group implicated in injury, repair, and fibrosis during this progress. However, the underlying mechanism of how macrophages participate in the development of the disease is largely unclear. CD11b (Integrin α M ) is highly expressed in monocytes/macrophages and has been verified to mediate broad functions. We found that CD11b‐knockout mice were protected from the ischemia/reperfusion‐induced AKI‐to‐CKD process. Additionally, renal macrophages from the kidneys of CD11b‐deficient mice presented an M2‐like, anti‐inflammatory phenotype. We demonstrated both in vitro and in vivo that enhanced alternative activation in CD11b‐knockout macrophages is regulated by the interleukin (IL)‐4/signal transducer and activator of transcription (STAT) 6 axis, which is mediated by the inactivation of the Src‐family kinase (SFK) member Lyn. Importantly, the therapeutical administration of CD11b‐neutralizing antibody can effectively prevent AKI‐to‐CKD progress. Thus, our study verifies that CD11b plays a critical role in limiting the alternative activation of macrophages and may be a potential therapeutic target during the AKI‐to‐CKD process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
Förderung
- National Natural Science Foundation of China
- Shanghai Clinical Research Center for Kidney Disease
- Shanghai Key Laboratory of Kidney and Blood Purification
- Shanghai Medical Centre of Kidney
- Shanghai Municipal Key Clinical Specialty
- Shanghai Federation of Nephrology Project supported by Shanghai ShenKang Hospital Development Center
Zitieren
APA
Zhou, H., Zhao, S., Zhou, M., Fang, Y., Tsuboi, N., Ding, X., & Shi, Y. (2024). CD11b deficiency attenuates the ischemia/reperfusion‐induced AKI‐to‐CKD process by regulating macrophage polarization. The FASEB Journal. https://doi.org/10.1096/fj.202402318r
Vancouver
Zhou H, Zhao S, Zhou M, Fang Y, Tsuboi N, Ding X, et al. CD11b deficiency attenuates the ischemia/reperfusion‐induced AKI‐to‐CKD process by regulating macrophage polarization. The FASEB Journal. 2024. doi:10.1096/fj.202402318r
BibTeX
@article{Zhou2024,
author = {Zhou, Huili and Zhao, Shuan and Zhou, Min and Fang, Yi and Tsuboi, Naotake and Ding, Xiaoqiang and Shi, Yiqin},
title = {CD11b deficiency attenuates the ischemia/reperfusion‐induced AKI‐to‐CKD process by regulating macrophage polarization},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202402318r}
}
EUVIMED